CoreCap Advisors’s TScan Therapeutics TCRX Stock Holding History

CoreCap Advisors’s Portfolio TCRX Stock Details TCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-166	Closed	-$229	–	3216
2025 Q1	$229	Buy	+166	New	+$359	﹤0.01%	2918

Other funds holding TCRX

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PBM

Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return

DMC

Deer Management Company Larchmont, New York $622M AUM 24.27% 1-Year Est. Return

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

SAM

Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

CoreCap Advisors's TCRX Position: Q2 2025 in Review

CoreCap Advisors sold out of TScan Therapeutics (TCRX) in Q2 2025, closing a stake of 166 shares — an estimated $229 sold.

CoreCap Advisors first reported a position in TCRX in Q1 2025 and held it in 1 quarter. The position peaked at $229 in Q1 2025. 81 funds tracked by Wall St. Rank hold TCRX as of Q2 2025.

CoreCap Advisors reported no remaining TScan Therapeutics position as of Q2 2025 after selling out during the quarter.
CoreCap Advisors sold 166 TScan Therapeutics shares in Q2 2025, an estimated $229.
CoreCap Advisors first reported a position in TScan Therapeutics in Q1 2025 and held it in 1 quarter.
CoreCap Advisors's TScan Therapeutics position peaked at $229 in Q1 2025.
81 funds tracked by Wall St. Rank held TScan Therapeutics as of Q2 2025.

Based on CoreCap Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.